Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) is a clinical-stage biotechnology company developing cell therapies for degenerative diseases, including ophthalmology and neurology programs. Five current, named analyst price targets were reviewed: H.C. Wainwright at $9, Canaccord Genuity at $9, Baird at $5, B. Riley Securities at $4, and D. Boral Capital at $3. The simple arithmetic mean of these targets is $6.00, with an approximate low-to-high range of $3 to $9.
The span between the lowest and highest target is extreme — the highest is three times the lowest — which underscores how differently analysts model the company's pipeline. The bullish $9 targets from H.C. Wainwright and Canaccord Genuity generally reflect confidence in the OpRegen program and the scalable AlloSCOPE manufacturing platform, while the lower $3–$4 targets reflect more conservative assumptions about clinical and commercialization timelines. There is no meaningful "hold" contingent in this group; all five firms carry Buy ratings, though their valuation assumptions diverge sharply. This calculated $6.00 mean is presented here as a mathematical average, not an officially published consensus.
LCTX closed near $1.03 in late October 2026, with a market capitalization of roughly $252 million. To reach $6, the shares would need to climb about 480%, which qualifies as a very large move rather than a modest or merely substantial one. The stock has already retraced well below its 52-week high of about $2.09, leaving the $6 objective far above even that prior peak.
The path to $6 would almost certainly require successful clinical data readouts, meaningful collaboration milestones, and a broader re-rating of the shares. Because the company is pre-revenue and relies on partnerships and milestone payments, valuation is driven primarily by pipeline news flow rather than current earnings or sales.
The shares have spent recent weeks consolidating near the psychologically important $1.00 level, with visible support around $0.88–$0.90 and shorter-term resistance near $1.05. The prior 52-week high near $2.09 sits far above the current price and represents a longer-term resistance zone, while the $1.00 mark serves as a durable reference point for market structure.
Analyst price targets generally reflect a roughly 12-month research horizon, though firms may differ in their assumptions. Investors should monitor clinical data updates from the OpRegen/RG6501 program, collaboration milestones with Genentech, progress on the AlloSCOPE platform and COR1 program, quarterly cash balances and any capital raises, and analyst target revisions, which have been frequent and occasionally large. Broader biotech risk appetite and rate expectations also matter for a speculative, pre-revenue name.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single indicator, the system scans for changing trends that traders can use to spot opportunities, keep tabs on existing positions, and react to momentum shifts more efficiently. Traders interested in a systematic layer of analysis can review the AI Daily Buy/Sell Signals to complement their own fundamental and technical research.
Reaching $6 would require Lineage Cell Therapeutics to multiply in value by roughly five times from its recent price near $1.03, a very large ascent even for a clinical-stage biotech. The calculated $6.00 mean sits between a cautious low of $3 and an optimistic high of $9, capturing both the genuine pipeline optionality — led by the Genentech-partnered OpRegen program — and the substantial execution, clinical, and financing risks that remain. The wide analyst spread and the stock's slide from its prior high suggest the market is demanding concrete clinical evidence before repricing the shares. The next data readouts, collaboration milestones, and cash position will likely determine whether the bull case or the bear case prevails.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with EDIT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To LCTX | 1D Price Change % | ||
|---|---|---|---|---|
| LCTX | 100% | -7.64% | ||
| EDIT - LCTX | 44% Loosely correlated | +1.40% | ||
| MDGL - LCTX | 43% Loosely correlated | +0.51% | ||
| IMNM - LCTX | 41% Loosely correlated | +0.37% | ||
| FHTX - LCTX | 41% Loosely correlated | +0.98% | ||
| VIR - LCTX | 40% Loosely correlated | -17.82% | ||
More | ||||